Forsøg på at modvirke denne reduktion i amprenavir AUC, ved at øge dosis af andre proteasehæmmere sammen med ritonavir, resulterede i en højere forekomst af leverpåvirkninger.
During attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with ritonavir, a high frequency of liver reactions was seen.